Presentations & Publications
2022
- Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it?
Meyer Sauteur PM, Chalker VJ, Berger C, Nir-Paz R, Beeton ML; ESGMAC and the ESGMAC–MyCOVID study group. Lancet Microbe. 2022 Aug 11:S2666-5247(22)00190-2. doi: 10.1016/S2666-5247(22)00190-2.
- Phenotypic and genotypic antimicrobial susceptibility patterns of the emerging human respiratory pathogen Mycoplasma amphoriforme isolated from the UK and Denmark.
Day J, Afshar B, Rowlands RS, Umer TS, Windsor H, Paukner S, Jensen JS, Spiller OB, Chalker VJ, Beeton ML; ESCMID Study Group for Mycoplasma and Chlamydia Infections (ESGMAC). J Antimicrob Chemother. 2022 Sep 1:dkac293. doi: 10.1093/jac/dkac293.
- Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021.
- Meyer Sauteur PM, Beeton ML, Uldum SA, Bossuyt N, Vermeulen M, Loens K, Pereyre S, Bébéar C, Keše D, Day J, Afshar B, Chalker VJ, Greub G, Nir-Paz R, Dumke R; ESGMAC–MyCOVID Study Team. Euro Surveill. 2022 May;27(19):2100746. doi: 10.2807/1560-7917.ES.2022.27.19.2100746.
2020
- Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016.
Beeton ML, Zhang XS, Uldum SA, et al. Euro Surveill 2020 doi: 10.2807/1560-7917.ES.2020.25.2.1900112.
CMI Website
eAcademy
EUCAST
